Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer

Resistance to docetaxel is a major clinical problem in advanced prostate cancer (PCa). Although glucocorticoids (GCs) are frequently used in combination with docetaxel, it is unclear to what extent GCs and their receptor, the glucocorticoid receptor (GR), contribute to the chemotherapy resistance. I...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Endocr Relat Cancer
Auteurs principaux: Kroon, Jan, Puhr, Martin, Buijs, Jeroen T, van der Horst, Geertje, Hemmer, Daniëlle M, Marijt, Koen A, Hwang, Ming S, Masood, Motasim, Grimm, Stefan, Storm, Gert, Metselaar, Josbert M, Meijer, Onno C, Culig, Zoran, van der Pluijm, Gabri
Format: Artigo
Langue:Inglês
Publié: Bioscientifica Ltd 2016
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4657186/
https://ncbi.nlm.nih.gov/pubmed/26483423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-15-0343
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires